Studien

Aktuelle Studien

Rekrutierend:



Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate risk, HR+/HER2- early breast cancer

__________________________________________________________________________________________________________
Rekrutierend:

PlanB-LT-FU-Registry

Long term follow up registry for outcome evaluation in HR-positive/HER2 negative early breast cancer patients treated within the prospective PlanB study and relapse free after 5 years of endocrine therapy

___________________________________________________________________________________________________________

Im Follow Up:


Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer

Haben Sie Interesse an der Teilnahme an einer klinischen Studie der WSG? Dann bewerben Sie sich mit Hilfe unseres Fragebogens!

 
   
  
 
WSG
WEST GERMAN STUDY GROUP

Wallstraße 10
41061 Mönchengladbach
Germany

FON + 49 (0) 2161. 5 66 23-0
FAX  + 49 (0) 2161. 5 66 23-19

wsg@wsg-online.com
www.wsg-online.com